✦ LIBER ✦

Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma

✍ Scribed by Palmer, Peter A.; Vinke, Jan; Evers, Pauline; Pourreau, Catherine; Oskam, Ralph; Roest, Gerda; Vlems, Frans; Becker, Lisa; Loriaux, Eveline; Franks, Christopher R.

Book ID: 122716348
Publisher: Elsevier Science
Year: 1992
Tongue: English
Weight: 876 KB
Volume: 28
Category: Article
ISSN: 0959-8049
DOI: 10.1016/0959-8049(92)90450-G

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase iii randomized trial of interleuki

Phase iii randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma

✍ Teresa Murray Law; Robert J. Motzer; Madhu Mazumdar; Kenneth W. Sell; Philip Wal 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 723 KB

Background. Treatment with interleukin-2 (IL-2) and lymphokine-activated killer cells (LAK) resulted in responses in some patients with advanced renal cell carcinoma (RCC). However, the relative therapeutic benefit of the addition of LAK to IL-2 was unknown. Methods. A randomized Phase I11 trial wa

The treatment of metastatic renal cell c

The treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2

✍ Gore, M.E.; Galligioni, E.; Keen, C.W.; Sorio, R.; Loriaux, E.M.; Grobben, H.C.; 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 621 KB

Modifications of plasma lipids, lipoprot

Modifications of plasma lipids, lipoproteins and apolipoproteins in advanced cancer patients treated with recombinant interleukin-2 and autologous lymphokine-activated killer cells

✍ C.L. Malmendier; J-F. Lontie; J.P. Sculier; D.Y. Dubois 📂 Article 📅 1988 🏛 Elsevier Science 🌐 English ⚖ 660 KB

Evaluation of the treatment of 62 patien

Evaluation of the treatment of 62 patients with advanced cancer by using lymphokine-activated killer cells plus interleukin-2

📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 136 KB

Prospective Randomized Trial of High-Dos

Prospective Randomized Trial of High-Dose Interleukin-2 Alone or in Conjunction With Lymphokine-Activated Killer Cells for the Treatment of Patients With Advanced Cancer

✍ Rosenberg, S. A.; Lotze, M. T.; Yang, J. C.; Topalian, S. L.; Chang, A. E.; Schw 📂 Article 📅 1993 🏛 Oxford University Press 🌐 English ⚖ 962 KB

A combination of subcutaneous recombinan

A combination of subcutaneous recombinant interleukin-2 and recombinant interferon-α in the treatment of advanced renal cell carcinoma or melanoma

✍ Vuoristo, Merisisko; Jantunen, Ismo; Pyrhönen, Seppo; Muhonen, Timo; Kellokumpu- 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 410 KB